Freshpet, Inc. (FRPT) earnings date
Feb 22, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 8 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | during market hours | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | before open | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | before open | 36 | 8-K |
| Q4 FY2025 | Mon, Feb 23, 2026 | before open | 54 | 8-K |
| Q3 FY2025 | Mon, Nov 3, 2025 | before open | 34 | 8-K |
| Q2 FY2025 | Mon, Aug 4, 2025 | before open | 35 | 8-K |
| Q1 FY2025 | Mon, May 5, 2025 | before open | 35 | 8-K |
| Q4 FY2024 | Thu, Feb 20, 2025 | before open | 51 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Freshpet, Inc. Reports Third Quarter 2026 Financial Results Delivers 10% Net Sales Growth Achieves Gross Margin of 45% and Adjusted Gross Margin of 50% Raises and Narrows 2026 Outlook Bedminster, N.J. – November 4, 2026 – Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter and nine months ended September 30, 2026." exhibit |
| Q3 FY2026 | "Outlook For full year 2026, the Company is updating its guidance and now expects the following:" exhibit |
| Q3 FY2026 | "For full year 2027, the Company expects:" exhibit |
| Q3 FY2026 | "These include statements regarding our belief in executing against our priorities, full year 2026 guidance and 2027 financial targets." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Freshpet, Inc. Reports Second Quarter 2026 Financial Results Delivers ~15% Net Sales Growth Raises 2026 Net Sales and Adjusted EBITDA Outlook Updates Long-Term Adjusted Gross Margin Target to >49% Bedminster, N.J. – August 5, 2026 – Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its second quarter and six months ended June 30, 2026." exhibit |
| Q2 FY2026 | "Outlook For full year 2026, the Company is updating its guidance and now expects the following:" exhibit |
| Q2 FY2026 | "For full year 2027, the Company now expects:" exhibit |
| Q2 FY2026 | "These include statements regarding our belief in the impact of our manufacturing expertise and omnichannel strategy, 2026 guidance and 2027 financial targets, and being uniquely positioned to capture a meaningful share of the category." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/FRPT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/FRPT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/FRPT/"><img src="https://veritasdata.dev/embed/FRPT.svg" alt="FRPT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/FRPT/)
Script
<script async src="https://veritasdata.dev/embed/FRPT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/FRPT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.